A Physics-Constrained Marcus-Theory Optimization Framework Restores Parameter Identifiability in Deep-Pocket Oncogenic Drug Kinetics: A KRAS G12C and STAT3 Case Study

In the microscopic world of drug development, scientists often face a frustrating paradox: a molecule that looks perfect on paper fails to work inside the human body. This happens because the standard tools used to predict how drugs behave are often too simple. They treat the inside of a cell like a uniform soup, ignoring the fact that many drug targets are hidden deep inside tiny, crowded pockets within proteins. These pockets are often so tight that they exclude the water that usually surrounds them. In the open ocean of the cell, water acts like a heavy, sluggish fluid that resists change. But deep inside a protein pocket, if the water is pushed out, the environment changes drastically, becoming more like a dry, solid material. This shift alters the energy required for a drug to bind to its target, a factor that traditional models frequently miss. Understanding this hidden environment is crucial, especially for fighting difficult cancers driven by stubborn proteins like KRAS and STAT3, which hide their most vulnerable spots deep within their structures.

A team of researchers from the University of Douala in Cameroon has developed a new way to look at this problem, creating a framework that connects the physics of these tiny, dry pockets to the speed at which drugs bind to them. They call their approach the Cluchagues-Marcus Framework. Instead of guessing how a drug behaves, they built a model that accounts for the specific physics of a water-free zone. They started with a theory originally designed to explain how electrons jump between molecules, which depends heavily on how much the surrounding environment has to rearrange itself to allow the jump. In a water-filled pocket, this rearrangement is difficult and energy-intensive. However, the researchers proposed that if a drug can enter a pocket where water has been excluded, the energy barrier drops significantly, potentially allowing the drug to bind much faster. To test this idea, they applied their model to two specific cancer targets: a mutant form of the KRAS protein and a region of the STAT3 protein, both known for having deep, hard-to-reach binding sites.

The researchers did not test this in a living cell or a petri dish; instead, they used powerful computer simulations to see if their mathematical model held up. They created thousands of synthetic scenarios, mimicking the behavior of drugs in both water-filled and water-excluded pockets. Their simulations showed that when water is excluded from a pocket, the energy required for the drug to bind drops by nearly ninety percent. This massive reduction in energy barrier means the drug can bind to its target much more quickly. In their specific examples, this change made the drug bind eight times faster for the KRAS target and nearly four times faster for the STAT3 target. However, they also discovered a strict rule: this speed-up only happens if the drug's natural attraction to the target is within a specific range. If the drug is too eager to bind, the change in the environment actually slows it down. This finding provides a precise boundary for when a dry pocket helps a drug and when it might hinder it.

A major part of their work was solving a puzzle about how scientists measure drug effectiveness. Usually, researchers try to figure out two things at once from a single experiment: how tightly a drug sticks to a target and how fast it falls off. The researchers proved mathematically that without extra information, these two numbers cannot be separated; they are mathematically tangled together. Their model showed that to get a clear answer, scientists must fix one of these values using a known physical constant or an independent measurement. They tested this idea using real-world data from hundreds of cancer cell lines treated with a drug called napabucasin. When they applied their new rules to this messy, real-life data, they found that the model worked exactly as predicted. The quality of the fit did not change when they anchored the data to a known value, but the calculated speed at which the drug fell off changed dramatically. This confirmed that their method for untangling these measurements is sound, even if the data itself is noisy.

The study concludes that while the idea of using dry, water-free pockets to speed up drug binding is physically plausible and mathematically consistent, it remains a hypothesis that has not yet been proven in a biological experiment. The researchers were careful to state that their work is a tool for generating ideas and refining how we think about drug kinetics, not a final proof that a specific drug works this way in a patient. They highlighted that their model relies on assumptions about the size of these pockets and the nature of the materials inside them, which are difficult to measure directly. Furthermore, the specific metal structures they imagined could create these dry pockets are currently theoretical and have not been demonstrated in a laboratory setting. The value of this work lies in its clarity: it offers a rigorous way to think about the hidden physics of drug binding and provides a new set of rules for analyzing how drugs interact with the deep, complex pockets of cancer proteins. By clarifying what can and cannot be learned from standard drug tests, this framework helps scientists design better experiments to eventually find the cures that are currently slipping through the cracks.